You are using an older browser version. Please use a supported version for the best MSN experience.

Not surprising Allergan is getting acquired now, says Mizuho managing director

AbbVie is buying Allergan for $188.24 per share, at a premium of almost 45 percent. Mizuho analyst Irina Koffler joins 'Squawk Box' to discuss the merger and Allergan CEO's track record.

Recent Videos

image beaconimage beaconimage beacon